What is PT-141 (Intranasal)?

PT-141 (Intranasal) (also known as Bremelanotide Nasal) is a 7-residue melanocortin receptor agonist (intranasal) with a molecular weight of 1025 Da and a plasma half-life of ~2-3 hr. Same MC4R agonism via olfactory delivery route. Faster onset of central effects. The compound is studied primarily in the body composition / training domain for the applications outlined above.

What is the standard dosing protocol for PT-141 (Intranasal)?

Conventional PT-141 (Intranasal) dosing is 1.5-3 mg prn before activity via intranasal. For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Will PT-141 (Intranasal) actually increase lean mass?

PT-141 (Intranasal)'s effect on body composition depends on which dimension of the anabolic cascade it engages. Direct anabolic pathway engagement is not the principal mechanism, but contributions to recovery, connective tissue, and inflammatory tone produce measurable body-composition shifts in trained users. Effect size is proportional to training stimulus and nutritional adequacy.

What does PT-141 (Intranasal) stack well with?

For body composition / training protocols, PT-141 (Intranasal) pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from PT-141 (Intranasal)'s primary mechanism (Same MC4R agonism via olfactory delivery route), producing additive or synergistic effects rather than receptor competition.

Home/ Compounds/ PT-141 (Intranasal)

PT-141 (Intranasal)

Body Composition

For the body-composition and physique community, PT-141 (Intranasal) is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Same MC4R agonism via olfactory delivery route Faster onset of central effects.. The ~2-3 hr pharmacokinetic profile determines training-day versus rest-day dosing, while the intranasal administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

Injury RecoveryFat LossLean MassStrengthBody Recomposition

Key Takeaways

Body composition lens: response to PT-141 (Intranasal) is proportional to training stimulus and nutritional adequacy.
Mechanism: Same MC4R agonism via olfactory delivery route.
Body composition dose: 1.5-3 mg prn before activity via intranasal; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Same MC4R agonism via olfactory delivery route. Faster onset of central effects. Body composition relevance of this mechanism depends on which dimension of the anabolic cascade PT-141 (Intranasal) engages: direct GH/IGF-axis activation, recovery-and-connective-tissue effects, or training-adjacent (sleep, inflammation) layers. The subsections below cover anabolic substrate, recovery window, training-day dosing, and hyperplasia versus hypertrophy.

Recovery window and training frequency

The most reliably reported effect of PT-141 (Intranasal) in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Hyperplasia and structural adaptation

Where PT-141 (Intranasal) demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. PT-141 (Intranasal) with a ~2-3 hr half-life of ~2-3 hr is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Body Composition / Training Applications

Body Recomposition

For body recomposition, PT-141 (Intranasal) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Cardiovascular Conditioning

The body composition community converges on PT-141 (Intranasal) for cardiovascular conditioning with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Training Performance

Training Performance responds to PT-141 (Intranasal) with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Injury Recovery

For injury recovery, PT-141 (Intranasal) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	1.5-3 mg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	1.5-3 mg	4–6 weeks initial cycle
Body Composition focus	Intranasal	1.5-3 mg	PRN before activity
Maintenance phase	Intranasal	1.5-3 mg	Ongoing with periodic pauses

Dose timing for PT-141 (Intranasal) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

PT-141 (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

PT-141 (Intranasal) + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with PT-141 (Intranasal)'s mechanism in body composition / training protocols.
PT-141 (Intranasal) + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with PT-141 (Intranasal)'s mechanism in body composition / training protocols.
PT-141 (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with PT-141 (Intranasal)'s mechanism in body composition / training protocols.
PT-141 (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with PT-141 (Intranasal)'s mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved formulation (injectable is approved)

Same as injectable PT-141; nasal irritation possible.

Lens-specific safety considerations for body composition / training use of PT-141 (Intranasal): Same as injectable PT-141; nasal irritation possible. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Bremelanotide clinical trials

PMID 31626723

PT-141 (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
PT-141 (Intranasal)	Melanocortin receptor agonist (intranasal)	~2-3 hr	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Can I use PT-141 (Intranasal) alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

Best stack pairing for lean mass?

The canonical lean mass stack pairs PT-141 (Intranasal) with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

Should I cycle PT-141 (Intranasal)?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

What is the regulatory status of PT-141 (Intranasal)?

PT-141 (Intranasal) regulatory status: Unapproved formulation (injectable is approved) in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does PT-141 (Intranasal)'s half-life affect dosing?

PT-141 (Intranasal) has a plasma half-life of ~2-3 hr, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under prn before activity dosing at 1.5-3 mg per dose explains the typical onset timeline for anabolic and recovery endpoints.

Clinical Protocol

Start a PT-141 (Intranasal) Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified PT-141 (Intranasal) and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 1025 Da
Sequence length: 7 aa
Half-life: ~2-3 hr
WADA: Not on prohibited list
FDA: Unapproved formulation (injectable is approved)

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for PT-141 (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for PT-141 (Intranasal)

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised